Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
PaperCitations, authors & open-access status
A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 105 citations, 2019 year and gold oa status.
105
Citations
2019
Year
gold
OA Status